CY1123573T1 - Ενωσεις βενζαμιδιων και νικοτιναμιδιων και μεθοδοι χρησεις των ιδιων - Google Patents

Ενωσεις βενζαμιδιων και νικοτιναμιδιων και μεθοδοι χρησεις των ιδιων

Info

Publication number
CY1123573T1
CY1123573T1 CY20201100959T CY201100959T CY1123573T1 CY 1123573 T1 CY1123573 T1 CY 1123573T1 CY 20201100959 T CY20201100959 T CY 20201100959T CY 201100959 T CY201100959 T CY 201100959T CY 1123573 T1 CY1123573 T1 CY 1123573T1
Authority
CY
Cyprus
Prior art keywords
benzamide
compounds
methods
same
nicotinamide
Prior art date
Application number
CY20201100959T
Other languages
English (en)
Inventor
Alexander Polinsky
Lioubov KOROTCHKINA
Slavoljub Vujcic
Olga CHERNOVA
Original Assignee
Oncotartis Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotartis Inc. filed Critical Oncotartis Inc.
Publication of CY1123573T1 publication Critical patent/CY1123573T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

Η παρούσα αποκάλυψη παρέχει ενώσεις βενζαμιδίων και νικοτιναμιδίων και φαρμακευτικές χρήσεις των ενώσεων. Οι ενώσεις μπορούν να χρησιμοποιηθούν για αγωγή, για παράδειγμα, καρκίνων όπως είναι οι αιμοποιητικοί καρκίνοι (π.χ., λευχαιμία). Οι προτιμώμενες ενώσεις της εφεύρεσης περιέχουν μια μερίδα φαινυλαιθυνυλίου ως επίσης και μια μερίδα ετεροκυκλυλίου ή ετεροαρυλίου βάσει αμινών προσαρτημένη στην ένωση βενζαμιδίου και νικοτιναμιδίου.
CY20201100959T 2013-12-24 2020-10-12 Ενωσεις βενζαμιδιων και νικοτιναμιδιων και μεθοδοι χρησεις των ιδιων CY1123573T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361920672P 2013-12-24 2013-12-24
PCT/US2014/072150 WO2015100322A1 (en) 2013-12-24 2014-12-23 Benzamide and nicotinamide compounds and methods of using same

Publications (1)

Publication Number Publication Date
CY1123573T1 true CY1123573T1 (el) 2022-03-24

Family

ID=53479649

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100959T CY1123573T1 (el) 2013-12-24 2020-10-12 Ενωσεις βενζαμιδιων και νικοτιναμιδιων και μεθοδοι χρησεις των ιδιων

Country Status (18)

Country Link
US (2) US10208032B2 (el)
EP (2) EP3756666A1 (el)
JP (3) JP6637890B2 (el)
KR (1) KR102412220B1 (el)
CN (3) CN110105340B (el)
AU (2) AU2014369926B2 (el)
BR (1) BR112016014954A2 (el)
CA (1) CA2933632C (el)
CL (1) CL2016001623A1 (el)
CY (1) CY1123573T1 (el)
EA (1) EA032355B1 (el)
ES (1) ES2829504T3 (el)
GE (1) GEP20186871B (el)
IL (2) IL246438B (el)
MX (1) MX2016008359A (el)
PL (1) PL3087051T3 (el)
PT (1) PT3087051T (el)
WO (1) WO2015100322A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3756666A1 (en) * 2013-12-24 2020-12-30 Oncotartis Inc. Nicotinamide compound for use in the treatment of cancer
TW201625578A (zh) 2014-04-18 2016-07-16 千禧製藥公司 喹啉化合物及其用途
CA2954328A1 (en) 2014-07-23 2016-01-28 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
WO2016118565A1 (en) 2015-01-20 2016-07-28 Millennium Pharmaceuticals, Inc. Quinazoline and quinoline compounds and uses thereof
WO2020260871A1 (en) * 2019-06-24 2020-12-30 Benevolentai Bio Limited New compounds and methods
US11767310B2 (en) 2021-08-10 2023-09-26 Abbvie Inc. Nicotinamide RIPK1 inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916145A (en) 1987-07-10 1990-04-10 Hoffmann-La Roche Inc. Substituted n-[(pyridyl)alkyl]aryl-carboxamide
US5557434A (en) * 1994-09-30 1996-09-17 Rockwell International Optical compensator including an o-plate for super-twist nematic liquid crystal display
ZA9510829B (en) * 1994-12-23 1996-07-03 Smithkline Beecham Corp 3,3-(disubstituted)cyclohexan-1-one monomers and related compounds
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
JPH10195063A (ja) * 1996-10-21 1998-07-28 Dai Ichi Seiyaku Co Ltd エチニルチアゾール誘導体
ID22426A (id) 1996-12-11 1999-10-14 Basf Ag Ketobenzamida yang baru dan penggunaannya
JP2003501436A (ja) * 1999-06-04 2003-01-14 バセル テクノロジー カンパニー ビー．ブイ． チタン錯体の製造法
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
WO2002078702A1 (en) 2001-03-30 2002-10-10 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CA2462442A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
PE20040804A1 (es) 2002-12-19 2004-12-31 Boehringer Ingelheim Pharma DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
CN1882529A (zh) * 2003-09-24 2006-12-20 梅特希尔基因公司 组蛋白脱乙酰基酶抑制剂
AU2004276337B2 (en) * 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1856097B1 (en) * 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
AU2006301458A1 (en) 2005-10-13 2007-04-19 Devgen N.V. Kinase inhibitors
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
WO2008071453A1 (en) * 2006-12-13 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 1,2-diarylacetylene derivatives of acyltryptophanols
EP1932831A1 (en) * 2006-12-13 2008-06-18 Bayer Schering Pharma Aktiengesellschaft 1,2-Diarylacetylene Derivatives of Acyltryptophanols
EP2176249A2 (en) 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH New chemical compounds
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
FR2926297B1 (fr) * 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
WO2009143404A1 (en) * 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
WO2010104307A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2010124047A1 (en) * 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
KR20120115237A (ko) * 2009-10-30 2012-10-17 어리어드 파마슈티칼스, 인코포레이티드 암 치료 방법 및 조성물
US20110212969A1 (en) * 2010-02-26 2011-09-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CN101885722B (zh) 2010-07-01 2013-07-24 中国科学院广州生物医药与健康研究院 杂环炔苯类化合物及其药用组合物和应用
EP2699237A4 (en) 2011-04-21 2014-11-12 Childrens Hosp Medical Center THERAPY FOR LEUKEMIA
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
CN103214480B (zh) * 2012-01-19 2015-12-16 中国科学院广州生物医药与健康研究院 吡唑并吡啶炔苯类化合物及其药用组合物和应用
JP2015514802A (ja) * 2012-04-25 2015-05-21 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｒａｆキナーゼ媒介疾患用の方法及び組成物
EP2712862A1 (en) * 2012-09-28 2014-04-02 Splicos New anti-invasive compounds
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN104211639A (zh) 2013-06-05 2014-12-17 中国科学院上海药物研究所 一类炔基杂环类化合物及其应用
EP3756666A1 (en) 2013-12-24 2020-12-30 Oncotartis Inc. Nicotinamide compound for use in the treatment of cancer

Also Published As

Publication number Publication date
KR20160095170A (ko) 2016-08-10
CN110105340B (zh) 2022-10-25
WO2015100322A1 (en) 2015-07-02
EP3087051A4 (en) 2017-07-12
JP2020073511A (ja) 2020-05-14
MX2016008359A (es) 2016-12-07
CN105980349A (zh) 2016-09-28
EP3756666A1 (en) 2020-12-30
IL246438A0 (en) 2016-08-31
AU2019250170B2 (en) 2020-08-27
PL3087051T3 (pl) 2021-02-22
US10208032B2 (en) 2019-02-19
ES2829504T3 (es) 2021-06-01
JP2017502960A (ja) 2017-01-26
IL246438B (en) 2020-02-27
AU2014369926B2 (en) 2019-07-18
IL272301B (en) 2020-11-30
CA2933632A1 (en) 2015-07-02
US20190031658A1 (en) 2019-01-31
GEP20186871B (en) 2018-06-25
EP3087051A1 (en) 2016-11-02
CN110016015A (zh) 2019-07-16
CA2933632C (en) 2022-06-21
JP7027393B2 (ja) 2022-03-01
CL2016001623A1 (es) 2016-12-30
CN110105340A (zh) 2019-08-09
JP2020073512A (ja) 2020-05-14
KR102412220B1 (ko) 2022-06-23
EA201600494A1 (ru) 2016-12-30
US20160347748A1 (en) 2016-12-01
JP6873221B2 (ja) 2021-05-19
AU2019250170A1 (en) 2019-10-31
EA032355B1 (ru) 2019-05-31
IL272301A (en) 2020-03-31
EP3087051B1 (en) 2020-07-15
AU2014369926A1 (en) 2016-07-14
JP6637890B2 (ja) 2020-01-29
PT3087051T (pt) 2020-10-21
CN110016015B (zh) 2021-06-25
BR112016014954A2 (pt) 2017-08-08
US10538520B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
CY1123573T1 (el) Ενωσεις βενζαμιδιων και νικοτιναμιδιων και μεθοδοι χρησεις των ιδιων
CY1124187T1 (el) Ετεροκυκλικα αμιδια ως αναστολεις κινασης
CY1124385T1 (el) Συζευγματα πυρρολοβενζοδιαζεπινων
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
CY1121129T1 (el) Αναστολεις toy fgfr4 πυριμιδινης
CY1121395T1 (el) Τετραϋδροπυριδοπυραζινες-διαμορφωτες toy gpr6
CY1123633T1 (el) Ετεροκυκλικες ενωσεις και οι χρησεις αυτων
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1119502T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις των σχετικων me janus (ιανος) kinασων (jak)
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CL2015002932A1 (es) Inhibidores de proteína quinasa
UY35434A (es) ?4-amino-6-(heterocíclico)picolinatos y 6-amino-2-(heterocíclico)pirimidin-4-carboxilatos y su uso como herbicidas?.
EA201891622A1 (ru) Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их
EA201600091A1 (ru) 4-членные кольцевые карбоксамиды, применяемые в качестве нематоцидов
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201591961A1 (ru) Ингибиторы акк и их применение
CY1123920T1 (el) Αντιγριπικο πολυκυκλικο παραγωγο πυριδονης και προφαρμακο αυτου
CL2017000792A1 (es) Derivados del ácido borónico
EA201591959A1 (ru) Ингибиторы акк и их применение
EA201591960A1 (ru) Ингибиторы акк и их применение
NI201500119A (es) Compuestos de heteroarilo y sus usos
EA201591962A1 (ru) Ингибиторы акк и их применение
CY1118883T1 (el) Μεθοδος παρασκευης βορτιοξετινης